MetrioPharm AG Investor Relations News
-
Investor-Update QI 2025
Extraordinary General Meeting of MetrioPharm AG, Save the Date: Annual General Meeting of MetrioPharm AG, Company Calendar 2025, MetrioPharm AG informs
-
Investor-Update QIV 2024
Milestones from the COVID-19 trial, Focus on rare diseases: DMD, Outlook 2025: Financing and further development, MetrioPharm AG Company Calendar 2025, MetrioPharm AG informs
-
Investor Relations News QIII 2024
Mode of Action of MetrioPharm's Lead Molecule MP1032, MetrioPharm AG Company Calendar 2024, MetrioPharm AG informs
-
Investor Relations News QII 2024
18th Annual General Meeting of MetrioPharm AG, MetrioPharm AG Company Calendar 2024, MetrioPharm AG informs
-
Investor Relations News QI 2024
Development Update from CSO Dr. Wolfgang Brysch, Company Calendar, MetrioPharm informs
-
Investor Relations News QIV 2023
Holiday Greetings from CEO Thomas Christély, MetrioPharm AG Company Calendar in H1 2024, MetrioPharm AG informs
-
Investor Relations News QIII 2023
Financing Round Continues, Development in Duchenne Muscular Dystrophy (DMD), MetrioPharm Company Calendar H2, MetrioPharm informs
-
Investor Relations News QII 2023
MetrioPharm AG has started a new financing round, 17th Annual General Meeting of MetrioPharm AG, Company Calendar, MetrioPharm informs
-
Investor Relations News QI 2023
Invitation to a Webinar, Company Calendar, MetrioPharm informs
-
Investor Relations News QIV 2022
Holiday Greetings from CEO Thomas Christély